CHA Biotech FY 2025 Annual Report
Beta

Filed: March 31, 2026· period ending December 31, 2025DART

CHA Biotech annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 31, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).

CHA Biotech FY 2025 Annual Report Analysis

Business Overview

• Revenue mix FY2025: medical services 58.65%, products (pharmaceutical, cosmetics) 9.61%, global CDMO and others 31.74%
• Signed license-out agreement Mar 2023 with Astellas Institute of Regenerative Medicine for RPE and Blastomere tech, total contract KRW 42.2B

Management Discussion & Analysis

• Revenue KRW 1.2683T (+21.36% YoY); Operating loss KRW 48.8B (loss narrowed by KRW 10.9B); Net loss KRW 150.8B (+1202.93%)
• Hospital sales contributed KRW 743.9B (+16.57%), driven by US Hollywood hospital and Australian IVF service expansion

Risk Factors

• USD 10% exchange rate move → ±KRW 356M impact on profit for FY2025, similar to ±KRW 372M prior year
• Financial liabilities contractually due within 1 year KRW 1.35T in FY2025, up from KRW 1.04T in prior year

CHA Biotech FY 2025 Key Financial Metrics
DART

Total Assets

KRW 2.55T

▲ +16.6% YoY

Operating Cash Flow

-KRW 72.5B

▼ -46.4% YoY

CapEx

KRW 147.0B

▲ +56.5% YoY

Source: KIFRS consolidated financial data from CHA Biotech annual report on DART. All figures in KRW.

Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding